Novartis Gets FDA Approval for Expanded Pluvicto Indication

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Novartis Gets FDA Approval for Expanded Pluvicto Indication

, MT Newswires - 1:46 PM ET 3/28/2025 Company News

01:46 PM EDT, 03/28/2025 (MT Newswires) -- Novartis ( NVS ) said Friday the US Food and Drug Administration has approved its radioligand therapy Pluvicto for earlier use before chemotherapy in prostate cancer patients.

The new indication allows the use in patients with metastatic castration-resistant prostate cancer who have been treated with an androgen receptor pathway inhibitor therapy and are considered appropriate to delay chemotherapy, Novartis ( NVS ) said.

The approval triples the number of patient population eligible to receive Pluvicto, the company said.

Price: 112.29, Change: +0.89, Percent Change: +0.80

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.